nalmefene (JKB-121) / TaiwanJ - LARVOL DELTA

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives. (PubMed, Clin Mol Hepatol) - "Immunological modulations targeting hepatocyte death, inflammatory reactions and gut microbiome include N-acetylcysteine, selonsertib, F-652, prednisone, pentoxifylline, anakinra, JKB-121, HA35, obeticholic acid, probiotics, prebiotics, antibiotics and FMT. Understanding the immunological mechanisms underlying in SLD is crucial for advancing clinical therapeutic strategies."

Journal • Fibrosis • Gastrointestinal Cancer • Hepatology • Immunology • Liver Cancer • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor • CD4

Patient Driven Recovery With Nalmefene and Coaching (clinicaltrials.gov) - P1; N=10; Completed; Sponsor: Yale University; Phase classification: P2 ➔ P1

Clinical • Phase classification

Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia (clinicaltrials.gov) - P4; N=520; Not yet recruiting; Sponsor: RenJi Hospital

Clinical • New P4 trial • Anesthesia